{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T23:15:09Z","timestamp":1793488509558,"version":"4.5.0"},"reference-count":28,"publisher":"The Journal of Rheumatology","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>The duration of treatment with glucocorticoids (GC) in polymyalgia rheumatica (PMR) is often longterm. Amino bisphosphonates (N-BP) are used in PMR for the prevention of GC-induced osteoporosis, but they coulsd also have immunomodulatory properties. Whether they can be effective as an adjuvant treatment in PMR is unknown. We aimed to establish whether the use of N-BP in our PMR cohort may be associated with GC discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We conducted a retrospective review of all patients diagnosed with PMR recorded in our electronic medical notes. Cox regression analyses were used to examine the association between the use of N-BP and discontinuation of GC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Data were retrieved for 385 patients (mean age 71 \u00b1 10 yrs, 64% females, mean initial prednisone dose 19 \u00b1 9 mg\/day). The median followup time was 38 months (range 9\u201357); more than 60% of patients were exposed to N-BP. GC were discontinued in 47% of patients after a median time of 20 months (range 14\u201327), but subsequently restarted in 39%. Overall, 276\/385 patients (72%) were actively treated at their last available evaluation (mean prednisone dose 4.9 \u00b1 5.5 mg\/day), while 123\/205 (60%) were still receiving GC after 24 months of followup. The use of N-BP was associated with the discontinuation of GC (adjusted HR 0.66, 95% CI 0.50\u20130.88), independent of age, initial GC dose, and osteoporosis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Unlike current guidelines, longterm treatment with GC is often necessary. These preliminary data suggest that N-BP may be involved in the management of PMR.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.180324","type":"journal-article","created":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T07:15:21Z","timestamp":1541056521000},"page":"318-322","source":"Crossref","is-referenced-by-count":15,"title":["Permanent Discontinuation of Glucocorticoids in Polymyalgia Rheumatica Is Uncommon but May Be Enhanced by Amino Bisphosphonates"],"prefix":"10.3899","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9355-7673","authenticated-orcid":false,"given":"Alessandro","family":"Giollo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9692-2293","authenticated-orcid":false,"given":"Maurizio","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bettili","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Ghellere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Fracassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Idolazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Gatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ombretta","family":"Viapiana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,11,1]]},"reference":[{"key":"2019030109253060000_46.3.318.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.5444"},{"key":"2019030109253060000_46.3.318.2","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1016\/S0140-6736(17)31825-1","article-title":"Polymyalgia rheumatica","volume":"390","author":"Gonz\u00e1lez-Gay","year":"2017","journal-title":"Lancet"},{"key":"2019030109253060000_46.3.318.3","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/nrrheum.2017.142","article-title":"Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities","volume":"13","author":"Dejaco","year":"2017","journal-title":"Nat Rev Rheumatol"},{"key":"2019030109253060000_46.3.318.4","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(85)90309-2"},{"key":"2019030109253060000_46.3.318.5","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker017"},{"key":"2019030109253060000_46.3.318.6","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1002\/acr.23320","article-title":"Comparable rates of glucocorticoid-associated adverse events in patients with polymyalgia rheumatica and comorbidities in the general population","volume":"70","author":"Shbeeb","year":"2018","journal-title":"Arthritis Care Res"},{"key":"2019030109253060000_46.3.318.7","first-page":"1","article-title":"Glucocorticoid withdrawal in polymyalgia rheumatica: the theory versus the practice","volume":"35","author":"Yates","year":"2017","journal-title":"Clin Exp Rheumatol"},{"key":"2019030109253060000_46.3.318.8","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780401022"},{"key":"2019030109253060000_46.3.318.9","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.110851"},{"key":"2019030109253060000_46.3.318.10","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12916-017-0987-1","article-title":"Risk of fracture among patients with polymyalgia rheumatica and giant cell arteritis: a population-based study","volume":"16","author":"Paskins","year":"2018","journal-title":"BMC Med"},{"key":"2019030109253060000_46.3.318.11","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/acr.23279","article-title":"2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis","volume":"69","author":"Buckley","year":"2017","journal-title":"Arthritis Care Res"},{"key":"2019030109253060000_46.3.318.12","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.2174\/138161210793563626","article-title":"Alternative use of bisphosphonate therapy for rheumatic disease","volume":"16","author":"Le Goff","year":"2010","journal-title":"Curr Pharm Des"},{"key":"2019030109253060000_46.3.318.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket321"},{"key":"2019030109253060000_46.3.318.14","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200329"},{"key":"2019030109253060000_46.3.318.15","doi-asserted-by":"publisher","DOI":"10.1002\/art.20901"},{"key":"2019030109253060000_46.3.318.16","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-012-2580-4"},{"key":"2019030109253060000_46.3.318.17","doi-asserted-by":"crossref","first-page":"ITC65","DOI":"10.7326\/AITC201705020","article-title":"Polymyalgia rheumatica","volume":"166","author":"Matteson","year":"2017","journal-title":"Ann Intern Med"},{"key":"2019030109253060000_46.3.318.18","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-207492"},{"key":"2019030109253060000_46.3.318.19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.4081\/reumatismo.2017.922","article-title":"Prevalence and incidence of osteoporotic fractures in patients on long-term glucocorticoid treatment for rheumatic diseases: the Glucocorticoid Induced OsTeoporosis TOol (GIOTTO) study","volume":"69","author":"Rossini","year":"2017","journal-title":"Reumatismo"},{"key":"2019030109253060000_46.3.318.20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s00223-013-9750-6","article-title":"Acute phase response after zoledronic acid is associated with long-term effects on white blood cells","volume":"93","author":"Rossini","year":"2013","journal-title":"Calcif Tissue Int"},{"key":"2019030109253060000_46.3.318.21","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.521"},{"key":"2019030109253060000_46.3.318.22","doi-asserted-by":"publisher","DOI":"10.1007\/s00223-012-9647-9"},{"key":"2019030109253060000_46.3.318.23","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10787-015-0233-4","article-title":"Effect of bisphosphonates treatment on cytokine imbalance between TH17 and Treg in osteoporosis","volume":"23","author":"Talaat","year":"2015","journal-title":"Inflammopharmacology"},{"key":"2019030109253060000_46.3.318.24","doi-asserted-by":"publisher","DOI":"10.1002\/art.34647"},{"key":"2019030109253060000_46.3.318.25","doi-asserted-by":"publisher","DOI":"10.1196\/annals.1351.030"},{"key":"2019030109253060000_46.3.318.26","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kep395"},{"key":"2019030109253060000_46.3.318.27","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1080\/1744666X.2016.1178572","article-title":"Recent advances in the diagnosis and treatment of polymyalgia rheumatica","volume":"12","author":"Muratore","year":"2016","journal-title":"Expert Rev Clin Immunol"},{"key":"2019030109253060000_46.3.318.28","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60680-1"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.180324","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T12:27:25Z","timestamp":1551443245000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.180324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,1]]},"references-count":28,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2019,3,1]]},"published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.3899\/jrheum.180324"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.180324","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,11,1]]}}}